1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Sartorius AG

Sartorius AG

SRT3.DE
Sartorius AGDE flagDeutsche Börse
239.20
EUR
-3.70
- -
16.52BMarket Cap
Sartorius AG
SRT3.DE
(Deutsche Börse)

Recent

price

244.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
9.67
10.75
12.4
11.61
13.07
16.35
19.01
20.54
22.9
26.71
34.14
50.42
61.02
49.63
49.01
51.24
39.14
Revenue per Share
0.6
0.61
0.71
0.77
0.71
1.85
1.51
1.68
2.07
2.29
3.07
4.66
9.91
3.01
1.22
2.24
2.63
Basic EPS, GAAP
1.05
0.4
-0.14
1.51
1.9
1.84
2.49
3.02
3.58
5.52
7.48
12.76
10.73
4.3
8.21
5.72
5.27
Free Cash Flow per Basic Share
0.14
0.15
0.2
0.24
0.25
0.35
0.38
0.45
0.5
0.62
0.35
0.71
1.26
1.43
0.74
0.74
0.73
Dividend per Share
2.79
3.22
0.25
0.25
0.25
0.25
1
1
1
1
1
1
1
1
1
1
1
Book Value per Share
-1.11
-1.42
-1.62
-1.44
-0.79
0.44
0.02
-4.02
-1.31
-0.5
-12.32
-10.78
-5.01
-40.16
-22.78
-20.72
-20.18
Tangible Book Value per Share
68
68
68
68
68
68
68
68
68
68
68
68
68
68
69
69
69
Basic Weighted Avg Shares
659
733
846
792
891
1,115
1,300
1,405
1,566
1,827
2,336
3,449
4,175
3,396
3,381
3,538
2,711
Sales/Revenue/Turnover
10.93
14.51
14.53
14.65
14.6
18.99
19.05
18.72
19.2
19.89
21.89
27.06
27.29
16.02
12.93
16.09
16.82
Operating Margin (%)
32
33
41
48
55
59
76
98
113
133
180
231
287
342
416
420
320
Depreciation Expense
41
42
49
52
48
126
103
115
141
157
210
319
678
206
84
155
182
Net Income, GAAP
35.13
33.21
31.59
30.71
33.65
31.9
28.96
20.81
27.05
27.85
29.47
36.12
22.73
24.85
26.45
31.6
32.89
Effective Tax Rate (%)
6.17
5.67
5.74
6.62
5.44
11.33
7.92
8.17
9.03
8.58
9
9.25
16.24
6.05
2.48
4.38
6.71
Profit Margin (%)
40
48
34
146
187
206
223
278
273
188
338
250
220
627
669
-201
-190
Working Capital
207
271
247
369
379
366
452
887
895
881
1,892
1,738
1,986
5,023
4,167
3,356
3,337
LT Debt
327
366
404
450
498
645
737
807
973
1,093
1,380
1,720
2,659
2,758
3,898
3,867
3,891
Total Equity
7.87
11.15
11.43
9.79
9.67
14.47
14.64
13.26
11.37
12.23
12.36
15.65
18.53
5.93
3.79
4.59
3.63
Return on Invested Capital (%)
11.56
7.31
8.1
9.1
7.47
19.27
10.29
8.23
7.61
7.8
6.95
8.93
15.99
4.91
2.81
3.52
4.58
Return on Capital (%)
21.65
20.27
40.95
307.53
284.47
739.83
240.82
167.76
206.68
229.12
307.15
466.17
991.37
300.58
122.27
224.33
263.43
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
926
964
LT Borrowings
- -
3,184
3,169
LT Finance Leases
- -
172
168
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
13,698
17,111
14,677

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,766
1,923
Cash, Cash Equivalents & STI
- -
552
600
Accounts Receivable, Net
- -
225
304
Inventories
- -
792
827
Total Current Liabilities
- -
1,967
2,113
Payables & Accruals
- -
- -
- -
ST Debt
- -
926
964
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.65%
24.7%
-0.78%
Free Cash Flow
22.27%
11.45%
-30.23%
Net Income, GAAP
18.11%
24%
84.4%
Sales/Revenue/Turnover
13.49%
10.85%
4.66%
Total Cash Common Dividend
16.23%
28.58%
0.2%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
820
861
794
907
3,381
2025
883
884
- -
928
3,538
2026
899
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.53
0.34
0.12
- -
1.22
2025
0.7
0.47
- -
- -
2.24
2026
0.81
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.74
2025
- -
- -
- -
- -
0.74
2026
0.73
- -
- -
- -
- -
Similar Companies
PlexBio Co., Ltd. (6572.TWO)
Paradigm Medical Industries, Inc. (PDMI)
Hogy Medical Co.,Ltd. (3593.T)
Suzhou Iron Technology CO.,LTD. (688329.SS)
JINS HOLDINGS Inc. (JNDOF)
Tetratherix Ltd. (TTX.AX)
Business
Sartorius Aktiengesellschaft operates as a premier international partner for the life science research community and the biopharmaceutical industry, delivering essential solutions globally. The company's comprehensive offerings are organized into two key divisions. The Bioprocess Solutions segment provides a wide range of products and services covering the entire biopharmaceutical production workflow. This includes advanced bioreactor systems like single-use, benchtop, and stainless steel models for cell culture and microbial fermentation, alongside specialized cell culture media and reagents, viral vaccines media, and regenerative medicine media. This division also encompasses purification and separation technologies such as membranes, process filtration, and chromatography products, as well as fluid management solutions, analytics, and software applications for process development and manufacturing. The Lab Products & Services segment offers innovative tools and consumables tailored for research and quality control laboratories within pharmaceutical and biopharmaceutical companies, as well as academic institutions. Its portfolio features high-precision laboratory instruments including weighing systems, pipetting and dispensing devices, water purification systems, and centrifuges. Additionally, it supplies an array of lab filtration products, live-cell analysis systems, flow cytometry platforms, and label-free detection technologies like surface plasmon resonance (SPR) and biolayer interferometry. The company further extends its support through services such as bioprocess development, protein expression systems, media and process optimization, testing, instrument maintenance, and validation support, along with OEM solutions. Sartorius serves a diverse clientele across life science research, biopharmaceutical manufacturing, quality control, and various applied industries. Founded in 1870, the company maintains its headquarters in Göttingen, Germany, and consistently expands its portfolio through strategic acquisitions and internal development to simplify and accelerate progress in the creation of new therapies and more affordable medicine. Recent strategic moves include investments in global manufacturing and research infrastructure, coupled with acquisitions aimed at enhancing capabilities in areas like advanced cell models.